Dr Lal Pathlabs Ltd
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]
- Market Cap ₹ 28,287 Cr.
- Current Price ₹ 1,687
- High / Low ₹ 1,804 / 1,272
- Stock P/E 53.7
- Book Value ₹ 148
- Dividend Yield 0.83 %
- ROCE 28.5 %
- ROE 22.9 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 50.4%
Cons
- Stock is trading at 11.4 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 637 | 765 | 882 | 1,024 | 1,165 | 1,274 | 1,491 | 1,879 | 1,769 | 2,125 | 2,352 | 2,648 | |
| 486 | 562 | 651 | 768 | 882 | 946 | 1,083 | 1,366 | 1,308 | 1,544 | 1,684 | 1,893 | |
| Operating Profit | 151 | 204 | 230 | 256 | 283 | 328 | 408 | 512 | 461 | 581 | 668 | 755 |
| OPM % | 24% | 27% | 26% | 25% | 24% | 26% | 27% | 27% | 26% | 27% | 28% | 29% |
| 17 | 20 | 28 | 31 | 46 | 58 | 51 | 53 | 47 | 66 | 109 | 82 | |
| Interest | 0 | 0 | 1 | 1 | 1 | 15 | 15 | 29 | 34 | 29 | 22 | 22 |
| Depreciation | 32 | 32 | 26 | 31 | 36 | 68 | 70 | 76 | 82 | 136 | 134 | 154 |
| Profit before tax | 135 | 192 | 231 | 256 | 292 | 303 | 374 | 461 | 391 | 483 | 621 | 660 |
| Tax % | 32% | 34% | 34% | 34% | 33% | 26% | 25% | 25% | 25% | 28% | 20% | 23% |
| 92 | 126 | 152 | 168 | 195 | 223 | 280 | 345 | 292 | 347 | 497 | 508 | |
| EPS in Rs | 8.40 | 7.60 | 9.18 | 10.09 | 11.72 | 13.39 | 16.80 | 20.71 | 17.54 | 20.76 | 29.74 | 30.33 |
| Dividend Payout % | 9% | 16% | 16% | 22% | 26% | 45% | 60% | 29% | 34% | 43% | 40% | 68% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 12% |
| 3 Years: | 14% |
| TTM: | 13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 13% |
| 3 Years: | 22% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 0% |
| 3 Years: | 13% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 22% |
| 3 Years: | 23% |
| Last Year: | 23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 55 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 | 168 |
| Reserves | 238 | 397 | 503 | 693 | 847 | 933 | 1,134 | 1,389 | 1,606 | 1,717 | 2,051 | 2,305 |
| 27 | 0 | 0 | 0 | 0 | 0 | 0 | 385 | 281 | 142 | 151 | 193 | |
| 130 | 112 | 90 | 119 | 136 | 302 | 356 | 354 | 350 | 406 | 336 | 383 | |
| Total Liabilities | 449 | 592 | 676 | 896 | 1,067 | 1,318 | 1,573 | 2,211 | 2,320 | 2,349 | 2,621 | 3,049 |
| 119 | 130 | 121 | 173 | 173 | 297 | 300 | 371 | 361 | 1,104 | 1,051 | 1,143 | |
| CWIP | 1 | 4 | 17 | 9 | 3 | 11 | 9 | 14 | 5 | 6 | 3 | 7 |
| Investments | 49 | 74 | 134 | 174 | 214 | 253 | 171 | 1,062 | 1,213 | 213 | 416 | 513 |
| 280 | 384 | 404 | 540 | 677 | 757 | 1,093 | 764 | 740 | 1,026 | 1,151 | 1,386 | |
| Total Assets | 449 | 592 | 676 | 896 | 1,067 | 1,318 | 1,573 | 2,211 | 2,320 | 2,349 | 2,621 | 3,049 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 94 | 142 | 167 | 189 | 208 | 272 | 373 | 426 | 428 | 478 | 540 | 606 | |
| -86 | -148 | -134 | -166 | -93 | -19 | -195 | -449 | -288 | 32 | -293 | -382 | |
| 1 | 1 | -32 | 13 | -54 | -187 | -136 | 141 | -270 | -404 | -325 | -256 | |
| Net Cash Flow | 9 | -5 | 1 | 36 | 61 | 65 | 42 | 118 | -131 | 106 | -78 | -32 |
| Free Cash Flow | 63 | 100 | 118 | 123 | 170 | 224 | 338 | 358 | 390 | 429 | 488 | 436 |
| CFO/OP | 97% | 103% | 102% | 110% | 110% | 110% | 115% | 106% | 114% | 104% | 104% | 102% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 17 | 17 | 17 | 14 | 17 | 14 | 16 | 13 | 13 | 15 | 16 | 18 |
| Inventory Days | 37 | 31 | 33 | 44 | 40 | 70 | 38 | 32 | 22 | 28 | 26 | 29 |
| Days Payable | 89 | 88 | 97 | 104 | 110 | 143 | 132 | 101 | 131 | 154 | 130 | 126 |
| Cash Conversion Cycle | -35 | -41 | -47 | -45 | -54 | -59 | -79 | -55 | -96 | -111 | -88 | -79 |
| Working Capital Days | -10 | 28 | 15 | 18 | 1 | -16 | -25 | -57 | -61 | -46 | -28 | -25 |
| ROCE % | 51% | 48% | 44% | 38% | 34% | 33% | 35% | 32% | 22% | 26% | 30% | 29% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of Clinical Laboratories Count |
|
||||||||||
| No. of Patient Service Centers (PSCs) Count |
|||||||||||
| No. of Patients Mn |
|||||||||||
| No. of Pick-up Points (PUPs) Count |
|||||||||||
| No. of Samples Mn |
|||||||||||
| Swasthfit Contribution to Revenue % of Revenue |
|||||||||||
| Realization per Patient (RPP) Rs. |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Received An Appellate Order From Income Tax Department
16h - Income tax appeal allowed on July 16, 2026; ESOP expense deduction of ₹32.66 crore approved.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
22h - Q1 FY27 investor conference call scheduled for July 24, 2026 at 5:30 PM IST.
-
Update on board meeting
22h - Board meeting on July 24, 2026 to approve Q1 FY27 results and consider interim dividend.
-
Corporate Action-Board to consider Dividend
22h - Board meeting on July 24, 2026 will consider Q1 FY27 results and interim dividend.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Jul
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
Concalls
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Oct 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
May 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jul 2023TranscriptAI SummaryPPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022TranscriptPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jul 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Jun 2021Transcript PPT
-
May 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Jan 2021TranscriptAI SummaryPPT
-
Dec 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Nov 2020TranscriptAI SummaryPPT
-
Aug 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
Jul 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptPPT
-
Jun 2020Transcript PPT
-
May 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Feb 2020TranscriptAI SummaryPPT
-
Nov 2019TranscriptPPT
-
Nov 2019Transcript PPT
-
Nov 2019TranscriptAI SummaryPPT
-
Aug 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
Aug 2019TranscriptAI SummaryPPT
-
Jun 2019TranscriptPPT
-
Jun 2019Transcript PPT
-
May 2019TranscriptAI SummaryPPT
-
Mar 2019TranscriptPPT
-
Mar 2019Transcript PPT
-
Feb 2019TranscriptAI SummaryPPT
-
Dec 2018TranscriptPPT
-
Nov 2018Transcript PPT
-
Nov 2018TranscriptAI SummaryPPT
-
Sep 2018TranscriptPPT
-
Aug 2018Transcript PPT
-
Aug 2018TranscriptAI SummaryPPT
-
Jun 2018TranscriptPPT
-
Jun 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Feb 2018TranscriptAI SummaryPPT
-
Feb 2018TranscriptAI SummaryPPT
-
Dec 2017TranscriptPPT
-
Dec 2017Transcript PPT
-
Nov 2017TranscriptAI SummaryPPT
-
Sep 2017Transcript PPT
-
Aug 2017Transcript PPT
-
Jun 2017Transcript PPT
-
May 2017TranscriptAI SummaryPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Jul 2016TranscriptPPT
-
Jun 2016TranscriptPPT
-
Feb 2016TranscriptPPT
Largest Diagnostic Chain
It is the largest diagnostics chain with a Pan-India presence. The company has 75 years of experience in the field of diagnostics and has served 131 million patients in the last five years. Its test offerings range from basic preventive health packages like SwasthFit to the most advanced investigations, including Comprehensive Genomic Profiles, Myeloid testing for Hematological Malignancies, and Amyloid Typing Solutions. [1] [2]